- Healthcare (10)
- Litigation / Dispute Resolution (9)
- Intellectual Property (8)
- Clinical/Medical Negligence (4)
- Company/Commercial (4)
- Regulatory and compliance (4)
- Employment (3)
- Commodities (2)
- Competition/EU (2)
- Information Technology (2)
- Media/Entertainment/Sport (2)
- Banking / Finance (1)
- Corporate (1)
- Crime (1)
- Environment (1)
- Tax (1)
Sort By: Newest first | Oldest first
European Commission fines Servier and five generic companies for curbing entry of cheaper versions of cardiovascular medicine
The European Commission has imposed fines totalling €427.7m on the French pharmaceutical company Servier and five producers of generic medicines.
Antitrust and competition enforcement is changing fast: our report for multinationals from three global conferences
The world of antitrust/competition enforcement is changing more rapidly than ever. This evolving environment presents new challenges for companies.
In food marketing litigation, class certification is a major hurdle for would-be class plaintiffs, but a recent case may have lowered the bar with a flexible approach to class certification.
California GCI’s coming priority products list and the DTSC Strategic Plan — what do they mean for you?
The highly anticipated next step in California’s Green Chemistry Initiative (GCI) is the planned April 2014 release of the list of ‘priority products’.
DLA Piper has released the 3 February 2014 issue of its Health Alert, which focuses on judgments, legislation and reports in the health sector.
DLA Piper has released the 28 January 2014 issue of its Health Alert, which focuses on judgments, legislation and reports in the health sector.
The Australian High Court has delivered its first judgment that directly considers the patentability of methods of medical treatment.
A recent decision by the Court of Appeal provides useful guidance on the correct approach to defining the market in relation to pharmaceutical products.
Despite 20 states allowing the use of medicinal marijuana and two more allowing recreational marijuana use, employers remain unaffected.
Antitrust agencies amend premerger notification rules to clarify reporting of acquisitions of pharmaceutical patent rights
The new rules may cause an uptick in premerger notification filings in the pharmaceutical industry.
Offering healthcare solutions at consumers' fingertips? What you should know about FDA regulation of mobile medical apps
More than two years after the FDA issued draft guidance on ‘mobile medical applications’, the agency recently issued its final guidance.
DLA Piper has published the second issue of its Life Sciences Spotlight publication for 2013.
The US Supreme Court has ruled that certain patent claims owned by Myriad Genetics are invalid as products of nature.
DLA Piper has released the Q3 2013 edition of its Intellectual Property and Technology News — EMEA.
The 12 August 2013 issue of DLA Piper’s Health Alert is available now.
Following the surprise doping scandal involving Godolphin stables in Newmarket, Sheikh Mohammed Bin Rashid Al Maktoum has moved swiftly in response to the findings of the BHA.
Over the past 10 months, Grant Thornton and DLA Piper have launched a successful life sciences boardroom lunch series.
The 22 July 2013 issue of DLA Piper’s Health Alert is available now.
The Supreme Court in FTC v Actavis held 5-3 that reverse-payment settlements of Hatch-Waxman Act litigation must be analysed under the rule-of-reason standard on a case-by-case basis.
The Supreme Court has issued its decision in FTC v Actavis on the antitrust analysis of reverse-payment settlements of Hatch-Waxman Act litigation.